Page updated ·next FDA decision on the calendar·Data as of Oct 14, 2026 7:39 PM ET
Price into the decision (T-120)
Daily close, T-120 (8/23/24) through T+5. Run-up high $203.87 on 11/7/24, low $164.99 on 11/22/24 (T-120 to T-1). FDA decision 2/7/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 24, 2025, 14 days before the decision date, at-the-money options priced a move of ±5.4% through Feb 14, 2025 (the first listed expiry after the decision; ATM implied volatility 28%). The stock closed -1.2% at the first close across the decision and +0.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-02-07
DrugEMBLAVEO (aztreonam and avibactam)
IndicationComplicated Intra-abdominal Infection and Hosptial Acquired Pneumonia
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was EMBLAVEO (aztreonam and avibactam) approved by the FDA?
Yes. The FDA approved the application for EMBLAVEO (aztreonam and avibactam) on February 7, 2025, per the FDA's own record. The primary source is linked on this page.
What was EMBLAVEO (aztreonam and avibactam) under FDA review for?
The application covered Complicated Intra-abdominal Infection and Hosptial Acquired Pneumonia. The FDA approved the application on February 7, 2025.
How did ABBV stock react to the FDA decision?
On the decision day ABBV moved -1.2%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.